Hypogonadotrophic hypogonadism in type 2 diabetes

References

• Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann Intern Med 1992; 117: 807–811
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Khaw K T, Yen S S. Endogenous sex hormone levels in older adult men with diabetes mellitus. Am J Epidemiol 1990; 132: 895–901
   PubMed Web of Science ®Google Scholar
• Haffner S M. Sex hormones, obesity, fat distribution, type 2 diabetes and insulin resistance: epidemiological and clinical correlation. Int J Obes Relat Metab Disord 2000; 24(Suppl.2)S56–58
   Google Scholar
• Haffner S M, Karhapaa P, Mykkanen L, Laakso M. Insulin resistance, body fat distribution, and sex hormones in men. Diabetes 1994; 43: 212–219
   PubMed Web of Science ®Google Scholar
• Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 5462–5468
   PubMed Web of Science ®Google Scholar
• Bhatia V, Chaudhuri A, Tomar R, Dhindsa S, Ghanim H, Dandona P. Low testosterone and high C-reactive protein concentrations predict low hematocrit in type 2 diabetes. Diabetes Care 2006; 29: 2289–2294
   PubMed Web of Science ®Google Scholar
• Tomar R, Dhindsa S, Chaudhuri A, Mohanty P, Garg R, Dandona P. Contrasting testosterone concentrations in type 1 and type 2 diabetes. Diabetes Care 2006; 29: 1120–1122
   PubMed Web of Science ®Google Scholar
• Simon D, Preziosi P, Barrett-Connor E, Roger M, Saint-Paul M, Nahoul K, Papoz L. Interrelation between plasma testosterone and plasma insulin in healthy adult men: the Telecom Study. Diabetologia 1992; 35: 173–177
   PubMed Web of Science ®Google Scholar
• Phillips G B. Relationship between serum sex hormones and glucose, insulin and lipid abnormalities in men with myocardial infarction. Proc Natl Acad Sci USA 1977; 74: 1729–1733
   PubMed Web of Science ®Google Scholar
• Andersson B, Marin P, Lissner L, Vermeulen A, Bjorntorp P. Testosterone concentrations in women and men with NIDDM. Diabetes Care 1994; 17: 405–411
   PubMed Web of Science ®Google Scholar
• Goodman-Gruen D, Barrett-Connor E. Sex differences in the association of endogenous sex hormone levels and glucose tolerance status in older men and women. 2000; 23: 912–918
   Google Scholar
• Corona G, Mannucci E, Petrone L, Ricca V, Balercia G, Mansani R, Chiarini V, Giommi R, Forti G, Maggi M. Association of hypogonadism and type II diabetes in men attending an outpatient erectile dysfunction clinic. Int J Impot Res 2006; 18: 190–197
   PubMed Web of Science ®Google Scholar
• Dunn J F, Nisula B C, Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab 1981; 53: 58–68
   PubMed Web of Science ®Google Scholar
• Pardridge W M. Serum bioavailability of sex steroid hormones. Clin Endocrinol Metab 1986; 15: 259–278
   PubMedGoogle Scholar
• Morley J E, Patrick P, Perry H M, III. Evaluation of assays available to measure free testosterone. Metabolism 2002; 51: 554–559
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Verdonck L, Kaufman J M. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84: 3666–3672
   PubMed Web of Science ®Google Scholar
• Rosner W. An extraordinarily inaccurate assay for free testosterone is still with us. J Clin Endocrinol Metab 2001; 86: 2903
   PubMed Web of Science ®Google Scholar
• Winters S J, Kelley D E, Goodpaster B. The analog free testosterone assay: are the results in men clinically useful. Clin Chem 1998; 44: 2178–2182
   PubMed Web of Science ®Google Scholar
• Tripathy D DS, Garg R, Khaishagi A, Syed T, Dandona P. Hypogondotrophic hypogonadism in erectile dysfunction associated with type 2 diabetes mellitus: a common defect?. Metabol Syndr Relat Disord 2003; 1: 75–81
   PubMed Web of Science ®Google Scholar
• Kapoor D, Aldred H, Clark S, Channer K S, Jones T H. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007; 30: 911–917
   PubMed Web of Science ®Google Scholar
• Mulligan T, Frick M F, Zuraw Q C, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006; 60: 762–769
   PubMed Web of Science ®Google Scholar
• Oh J Y, Barrett-Connor E, Wedick N M, Wingard D L. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care 2002; 25: 55–60
   PubMed Web of Science ®Google Scholar
• Haffner S M, Shaten J, Stern M P, Smith G D, Kuller L. Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996; 143: 889–897
   Google Scholar
• Selvin E, Feinleib M, Zhang L, Rohrmann S, Rifai N, Nelson W G, Dobs A, Basaria S, Golden S H, Platz E A. Androgens and diabetes in men: results from the third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2007; 30: 234–238
   PubMed Web of Science ®Google Scholar
• Chang T C, Tung C C, Hsiao Y L. Hormonal changes in elderly men with non-insulin-dependent diabetes mellitus and the hormonal relationships to abdominal adiposity. Gerontology 1994; 40: 260–267
   PubMedGoogle Scholar
• Zumoff B, Strain G W, Miller L K, Rosner W, Senie R, Seres D S, Rosenfeld R S. Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab 1990; 71: 929–931
   PubMed Web of Science ®Google Scholar
• Laaksonen D E, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen T P, Salonen R, Rauramaa R, Salonen J T. Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol 2003; 149: 601–608
   PubMed Web of Science ®Google Scholar
• Kaplan S A, Meehan A G, Shah A. The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men?. J Urol 2006; 176: 1524–1527, discussion 1527–1528
   PubMed Web of Science ®Google Scholar
• Svartberg J. Epidemiology: testosterone and the metabolic syndrome. Int J Impot Res 2007; 19: 124–128
   PubMed Web of Science ®Google Scholar
• Laaksonen D E, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen T P, Valkonen V P, Salonen J T. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab 2005; 90: 712–719
   PubMed Web of Science ®Google Scholar
• Laaksonen D E, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen T P, Valkonen V P, Salonen R, Salonen J T. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004; 27: 1036–1041
   PubMed Web of Science ®Google Scholar
• Makhsida N, Shah J, Yan G, Fisch H, Shabsigh R. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol 2005; 174: 827–834
   PubMed Web of Science ®Google Scholar
• Haffner S M, Valdez R A, Mykkanen L, Stern M P, Katz M S. Decreased testosterone and dehydroepiandrosterone sulfate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men. Metabolism 1994; 43: 599–603
   PubMed Web of Science ®Google Scholar
• Woodhouse L J, Gupta N, Bhasin M, Singh A B, Ross R, Phillips J, Bhasin S. Dose-dependent effects of testosterone on regional adipose tissue distribution in healthy young men. J Clin Endocrinol Metab 2004; 89: 718–726
   PubMed Web of Science ®Google Scholar
• Seidell J C, Bjorntorp P, Sjostrom L, Kvist H, Sannerstedt R. Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism 1990; 39: 897–901
   PubMed Web of Science ®Google Scholar
• Tsai E C, Matsumoto A M, Fujimoto W Y, Boyko E J. Association of bioavailable, free, and total testosterone with insulin resistance: influence of sex hormone-binding globulin and body fat. Diabetes Care 2004; 27: 861–868
   PubMed Web of Science ®Google Scholar
• Pitteloud N, Hardin M, Dwyer A A, Valassi E, Yialamas M, Elahi D, Hayes F J. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab 2005; 90: 2636–2641
   PubMed Web of Science ®Google Scholar
• Pitteloud N, Mootha V K, Dwyer A A, Hardin M, Lee H, Eriksson K F, Tripathy D, Yialamas M, Groop L, Elahi D, Hayes F J. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 2005; 28: 1636–1642
   PubMed Web of Science ®Google Scholar
• Bojesen A, Kristensen K, Birkebaek N H, Fedder J, Mosekilde L, Bennett P, Laurberg P, Frystyk J, Flyvbjerg A, Christiansen J S, Gravholt C H. The metabolic syndrome is frequent in Klinefelter's syndrome and is associated with abdominal obesity and hypogonadism. Diabetes Care 2006; 29: 1591–1598
   PubMed Web of Science ®Google Scholar
• Dhindsa S, Bhatia V, Dhindsa G, Chaudhuri A, Gollapudi G, Dandona P. Effects of hypogonadism on body composition and bone mineral density in type 2 diabetic patients. Diabetes Care 2007; 30: 1860–1861
   PubMed Web of Science ®Google Scholar
• Cohen P G. The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt - a major factor in the genesis of morbid obesity. Med Hypotheses 1999; 52: 49–51
   PubMed Web of Science ®Google Scholar
• Kapoor D, Malkin C J, Channer K S, Jones T H. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf) 2005; 63: 239–250
   PubMed Web of Science ®Google Scholar
• Kapoor D, Channer K S, Jones T H. Rosiglitazone increases bioactive testosterone and reduces waist circumference in hypogonadal men with type 2 diabetes. Diab Vasc Dis Res 2008; 5: 135–137
   PubMed Web of Science ®Google Scholar
• Yialamas M A, Dwyer A A, Hanley E, Lee H, Pitteloud N, Hayes F J. Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2007; 92: 4254–4259
   PubMed Web of Science ®Google Scholar
• Sato T, Matsumoto T, Yamada T, Watanabe T, Kawano H, Kato S. Late onset of obesity in male androgen receptor-deficient (AR KO) mice. Biochem Biophys Res Commun 2003; 300: 167–171
   PubMed Web of Science ®Google Scholar
• Fan W, Yanase T, Nomura M, Okabe T, Goto K, Sato T, Kawano H, Kato S, Nawata H. Androgen receptor null male mice develop late-onset obesity caused by decreased energy expenditure and lipolytic activity but show normal insulin sensitivity with high adiponectin secretion. Diabetes 2005; 54: 1000–1008
   PubMed Web of Science ®Google Scholar
• Simpson E R, McInnes K J. Sex and fat - can one factor handle both. Cell Metab 2005; 2: 346–347
   Google Scholar
• Bhasin S, Storer T W, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell T J, Tricker R, Shirazi A, Casaburi R. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996; 335: 1–7
   PubMed Web of Science ®Google Scholar
• Bhasin S, Woodhouse L, Casaburi R, Singh A B, Bhasin D, Berman N, Chen X, Yarasheski K E, Magliano L, Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, Storer T W. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 2001; 281: E1172–1181
   PubMed Web of Science ®Google Scholar
• Singh R, Artaza J N, Taylor W E, Gonzalez-Cadavid N F, Bhasin S. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology 2003; 144: 5081–5088
   PubMed Web of Science ®Google Scholar
• Marin P, Oden B, Bjorntorp P. Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. J Clin Endocrinol Metab 1995; 80: 239–243
   PubMed Web of Science ®Google Scholar
• Marin P, Krotkiewski M, Bjorntorp P. Androgen treatment of middle-aged, obese men: effects on metabolism, muscle and adipose tissues. Eur J Med 1992; 1: 329–336
   PubMedGoogle Scholar
• Marin P, Holmang S, Jonsson L, Sjostrom L, Kvist H, Holm G, Lindstedt G, Bjorntorp P. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord 1992; 16: 991–997
   PubMed Web of Science ®Google Scholar
• Singh A B, Hsia S, Alaupovic P, Sinha-Hikim I, Woodhouse L, Buchanan T A, Shen R, Bross R, Berman N, Bhasin S. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab 2002; 87: 136–143
   PubMed Web of Science ®Google Scholar
• Liu P Y, Wishart S M, Celermajer D S, Jimenez M, Pierro I D, Conway A J, Handelsman D J. Do reproductive hormones modify insulin sensitivity and metabolism in older men? A randomized, placebo-controlled clinical trial of recombinant human chorionic gonadotropin. Eur J Endocrinol 2003; 148: 55–66
   PubMed Web of Science ®Google Scholar
• Tripathy D, Shah P, Lakshmy R, Reddy K S. Effect of testosterone replacement on whole body glucose utilisation and other cardiovascular risk factors in males with idiopathic hypogonadotrophic hypogonadism. Horm Metab Res 1998; 30: 642–645
   PubMedGoogle Scholar
• Kapoor D, Goodwin E, Channer K S, Jones T H. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006; 154: 899–906
   PubMed Web of Science ®Google Scholar
• Bruning J C, Gautam D, Burks D J, Gillette J, Schubert M, Orban P C, Klein R, Krone W, Muller-Wieland D, Kahn C R. Role of brain insulin receptor in control of body weight and reproduction. Science 2000; 289: 2122–2125
   PubMed Web of Science ®Google Scholar
• Burks D J, Font de Mora J, Schubert M, Withers D J, Myers M G, Towery H H, Altamuro S L, Flint C L, White M F. IRS-2 pathways integrate female reproduction and energy homeostasis. Nature 2000; 407: 377–382
   PubMed Web of Science ®Google Scholar
• Watanobe H, Hayakawa Y. Hypothalamic interleukin-1 beta and tumor necrosis factor-alpha, but not interleukin-6, mediate the endotoxin-induced suppression of the reproductive axis in rats. Endocrinology 2003; 144: 4868–4875
   PubMed Web of Science ®Google Scholar
• Russell S H, Small C J, Stanley S A, Franks S, Ghatei M A, Bloom S R. The in vitro role of tumour necrosis factor-alpha and interleukin-6 in the hypothalamic-pituitary gonadal axis. J Neuroendocrinol 2001; 13: 296–301
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Kaufman J M, Deslypere J P, Thomas G. Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism of obese men. J Clin Endocrinol Metab 1993; 76: 1140–1146
   PubMed Web of Science ®Google Scholar
• Giagulli V A, Kaufman J M, Vermeulen A. Pathogenesis of the decreased androgen levels in obese men. J Clin Endocrinol Metab 1994; 79: 997–1000
   PubMed Web of Science ®Google Scholar
• Blank D M, Clark R V, Heymsfield S B, Rudman D R, Blank M S. Endogenous opioids and hypogonadism in human obesity. Brain Res Bull 1994; 34: 571–574
   PubMed Web of Science ®Google Scholar
• Lima N, Cavaliere H, Knobel M, Halpern A, Medeiros-Neto G. Decreased androgen levels in massively obese men may be associated with impaired function of the gonadostat. Int J Obes Relat Metab Disord 2000; 24: 1433–1437
   PubMed Web of Science ®Google Scholar
• Strain G W, Zumoff B, Miller L K, Rosner W, Levit C, Kalin M, Hershcopf R J, Rosenfeld R S. Effect of massive weight loss on hypothalamic-pituitary-gonadal function in obese men. J Clin Endocrinol Metab 1988; 66: 1019–1023
   PubMed Web of Science ®Google Scholar
• Lin T, Haskell J, Vinson N, Terracio L. Characterization of insulin and insulin-like growth factor I receptors of purified Leydig cells and their role in steroidogenesis in primary culture: a comparative study. Endocrinology 1986; 119: 1641–1647
   PubMed Web of Science ®Google Scholar
• Mulligan T, Iranmanesh A, Kerzner R, Demers L W, Veldhuis J D. Two-week pulsatile gonadotropin releasing hormone infusion unmasks dual (hypothalamic and Leydig cell) defects in the healthy aging male gonadotropic axis. Eur J Endocrinol 1999; 141: 257–266
   Google Scholar
• Stanik S, Dornfeld L P, Maxwell M H, Viosca S P, Korenman S G. The effect of weight loss on reproductive hormones in obese men. J Clin Endocrinol Metab 1981; 53: 828–832
   PubMed Web of Science ®Google Scholar
• Isidori A M, Caprio M, Strollo F, Moretti C, Frajese G, Isidori A, Fabbri A. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab 1999; 84: 3673–3680
   PubMed Web of Science ®Google Scholar
• Khosla S, Melton L J, III, Atkinson E J, O'Fallon W M, Klee G G, Riggs B L. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998; 83: 2266–2274
   PubMed Web of Science ®Google Scholar
• Zumoff B, Miller L K, Strain G W. Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone. Metabolism 2003; 52: 1126–1128
   PubMed Web of Science ®Google Scholar
• Caprio M, Isidori A M, Carta A R, Moretti C, Dufau M L, Fabbri A. Expression of functional leptin receptors in rodent Leydig cells. Endocrinology 1999; 140: 4939–4947
   PubMed Web of Science ®Google Scholar
• Farooqi I S, Matarese G, Lord G M, Keogh J M, Lawrence E, Agwu C, Sanna V, Jebb S A, Perna F, Fontana S, Lechler R I, DePaoli A M, O'Rahilly S. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002; 110: 1093–1103
   PubMed Web of Science ®Google Scholar
• Seth A, Stanley S, Jethwa P, Gardiner J, Ghatei M, Bloom S. Galanin-like peptide stimulates the release of gonadotropin-releasing hormone in vitro and may mediate the effects of leptin on the hypothalamo-pituitary-gonadal axis. Endocrinology 2004; 145: 743–750
   Google Scholar
• Dandona P, Thusu K, Cook S, Snyder B, Makowski J, Armstrong D, Nicotera T. Oxidative damage to DNA in diabetes mellitus. Lancet 1996; 347: 444–445
   PubMed Web of Science ®Google Scholar
• Dandona P, Mohanty P, Ghanim H, Aljada A, Browne R, Hamouda W, Prabhala A, Afzal A, Garg R. The suppressive effect of dietary restriction and weight loss in the obese on the generation of reactive oxygen species by leukocytes, lipid peroxidation, and protein carbonylation. J Clin Endocrinol Metab 2001; 86: 355–362
   PubMed Web of Science ®Google Scholar
• Higdon J V, Frei B. Obesity and oxidative stress: a direct link to CVD. Arterioscler Thromb Vasc Biol 2003; 23: 365–367
   PubMed Web of Science ®Google Scholar
• Vincent H K, Powers S K, Stewart D J, Shanely R A, Demirel H, Naito H. Obesity is associated with increased myocardial oxidative stress. Int J Obes Relat Metab Disord 1999; 23: 67–74
   PubMed Web of Science ®Google Scholar
• Dandona P, Weinstock R, Thusu K, Abdel-Rahman E, Aljada A, Wadden T. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 1998; 83: 2907–2910
   PubMed Web of Science ®Google Scholar
• Hotamisligil G S, Shargill N S, Spiegelman B M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87–91
   PubMed Web of Science ®Google Scholar
• Katsuki A, Sumida Y, Murashima S, Murata K, Takarada Y, Ito K, Fujii M, Tsuchihashi K, Goto H, Nakatani K, Yano Y. Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1998; 83: 859–862
   PubMed Web of Science ®Google Scholar
• Madrid L V, Mayo M W, Reuther J Y, Baldwin A S, Jr. Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38. J Biol Chem 2001; 276: 18934–18940
   PubMed Web of Science ®Google Scholar
• Davi G, Guagnano M T, Ciabattoni G, Basili S, Falco A, Marinopiccoli M, Nutini M, Sensi S, Patrono C. Platelet activation in obese women: role of inflammation and oxidant stress. Jama 2002; 288: 2008–2014
   PubMed Web of Science ®Google Scholar
• Hotamisligil G S, Arner P, Caro J F, Atkinson R L, Spiegelman B M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409–2415
   PubMed Web of Science ®Google Scholar
• Hotamisligil G S, Peraldi P, Budavari A, Ellis R, White M F, Spiegelman B M. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996; 271: 665–668
   PubMed Web of Science ®Google Scholar
• Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25: 4–7
   PubMed Web of Science ®Google Scholar
• Burcelin R, Thorens B, Glauser M, Gaillard R C, Pralong F P. Gonadotropin-releasing hormone secretion from hypothalamic neurons: stimulation by insulin and potentiation by leptin. Endocrinology 2003; 144: 4484–4491
   PubMed Web of Science ®Google Scholar
• Aljada A, Ghanim H, Mohanty P, Kapur N, Dandona P. Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Egr)- 1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. J Clin Endocrinol Metab 2002; 87: 1419–1422
   PubMed Web of Science ®Google Scholar
• Aljada A, Ghanim H, Saadeh R, Dandona P. Insulin Inhibits NFkappaB and MCP-1 Expression in human aortic endothelial cells. J Clin Endocrinol Metab 2001; 86: 450–453
   Web of Science ®Google Scholar
• Aljada A, Saadeh R, Assian E, Ghanim H, Dandona P. Insulin inhibits the expression of intercellular adhesion molecule-1 by human aortic endothelial cells through stimulation of nitric oxide. J Clin Endocrinol Metab 2000; 85: 2572–2575
   PubMed Web of Science ®Google Scholar
• Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, Ahmad S. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect. J Clin Endocrinol Metab 2001; 86: 3257–3265
   PubMed Web of Science ®Google Scholar
• Pasquali R, Macor C, Vicennati V, Novo F, De lasio R, Mesini P, Boschi S, Casimirri F, Vettor R. Effects of acute hyperinsulinemia on testosterone serum concentrations in adult obese and normal-weight men. Metabolism 1997; 46: 526–529
   Google Scholar
• Aljada A, Ghanim H, Assian E, Dandona P. Tumor necrosis factor-alpha inhibits insulin-induced increase in endothelial nitric oxide synthase and reduces insulin receptor content and phosphorylation in human aortic endothelial cells. Metabolism 2002; 51: 487–491
   PubMed Web of Science ®Google Scholar
• Emanuelli B, Peraldi P, Filloux C, Sawka-Verhelle D, Hilton D, Van Obberghen E. SOCS-3 is an insulin-induced negative regulator of insulin signaling. J Biol Chem 2000; 275: 15985–15991
   PubMedGoogle Scholar
• Emanuelli B, Peraldi P, Filloux C, Chavey C, Freidinger K, Hilton D J, Hotamisligil G S, Van Obberghen E. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem 2001; 276: 47944–47949
   PubMed Web of Science ®Google Scholar
• Ghanim H, Aljada A, Daoud N, Deopurkar R, Chaudhuri A, Dandona P. Role of inflammatory mediators in the suppression of insulin receptor phosphorylation in circulating mononuclear cells of obese subjects. Diabetologia 2007; 50: 278–285
   Google Scholar
• Yesilova Z, Ozata M, Kocar I H, Turan M, Pekel A, Sengul A, Ozdemir I C. The effects of gonadotropin treatment on the immunological features of male patients with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2000; 85: 66–70
   Google Scholar
• Kanda N, Tsuchida T, Tamaki K. Testosterone inhibits immunoglobulin production by human peripheral blood mononuclear cells. Clin Exp Immunol 1996; 106: 410–415
   PubMed Web of Science ®Google Scholar
• Hatakeyama H, Nishizawa M, Nakagawa A, Nakano S, Kigoshi T, Uchida K. Testosterone inhibits tumor necrosis factor-alpha-induced vascular cell adhesion molecule-1 expression in human aortic endothelial cells. FEBS Lett 2002; 530: 129–132
   PubMed Web of Science ®Google Scholar
• Malkin C J, Pugh P J, Jones R D, Kapoor D, Channer K S, Jones T H. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 2004; 89: 3313–3318
   PubMed Web of Science ®Google Scholar
• Ng M K, Liu P Y, Williams A J, Nakhla S, Ly L P, Handelsman D J, Celermajer D S. Prospective study of effect of androgens on serum inflammatory markers in men. Arterioscler Thromb Vasc Biol 2002; 22: 1136–1141
   PubMed Web of Science ®Google Scholar
• Libby P, Ridker P M, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135–1143
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115–126
   PubMed Web of Science ®Google Scholar
• Liu P Y, Death A K, Handelsman D J. Androgens and cardiovascular disease. Endocr Rev 2003; 24: 313–340
   PubMed Web of Science ®Google Scholar
• Rosano G M, Sheiban I, Massaro R, Pagnotta P, Marazzi G, Vitale, Mercuro G, Volterrani M, Aversa A, Fini M. Low testosterone levels are associated with coronary artery disease in male patients with angina. Int J Impot Res 2007; 19: 176–182
   PubMed Web of Science ®Google Scholar
• Hak A E, Witteman J C, de Jong F H, Geerlings M I, Hofman A, Pols H A. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab 2002; 87: 3632–3639
   PubMed Web of Science ®Google Scholar
• Smith G D, Ben-Shlomo Y, Beswick A, Yarnell J, Lightman S, Elwood P. Cortisol, testosterone, and coronary heart disease: prospective evidence from the Caerphilly study. Circulation 2005; 112: 332–340
   PubMed Web of Science ®Google Scholar
• Laughlin G A, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008; 93: 68–75
   PubMed Web of Science ®Google Scholar
• Makinen J, Jarvisalo M J, Pollanen P, Perheentupa A, Irjala K, Koskenvuo M, Makinen J, Huhtaniemi I, Raitakari O T. Increased carotid atherosclerosis in andropausal middle-aged men. J Am Coll Cardiol 2005; 45: 1603–1608
   PubMed Web of Science ®Google Scholar
• Svartberg J, von Muhlen D, Mathiesen E, Joakimsen O, Bonaa K H, Stensland-Bugge E. Low testosterone levels are associated with carotid atherosclerosis in men. J Intern Med 2006; 259: 576–582
   PubMed Web of Science ®Google Scholar
• Rosano G M, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerquetani E, della Monica P L, Bonfigli B, Volpe M, Chierchia S L. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 1999; 99: 1666–1670
   PubMed Web of Science ®Google Scholar
• Webb C M, McNeill J G, Hayward C S, de Zeigler D, Collins P. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 1999; 100: 1690–1696
   PubMed Web of Science ®Google Scholar
• English K M, Steeds R P, Jones T H, Diver M J, Channer K S. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation 2000; 102: 1906–1911
   PubMed Web of Science ®Google Scholar
• Alexandersen P, Haarbo J, Byrjalsen I, Lawaetz H, Christiansen C. Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits. Circ Res 1999; 84: 813–819
   PubMed Web of Science ®Google Scholar
• Mukherjee T K, Dinh H, Chaudhuri G, Nathan L. Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: implications in atherosclerosis. Proc Natl Acad Sci USA 2002; 99: 4055–4060
   PubMed Web of Science ®Google Scholar
• Nathan L, Shi W, Dinh H, Mukherjee T K, Wang X, Lusis A J, Chaudhuri G. Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase. Proc Natl Acad Sci USA 2001; 98: 3589–3593
   PubMed Web of Science ®Google Scholar
• Makinen J, Jarvisalo M J, Pollanen P, Perheentupa A, Irjala K, Koskenvuo M, Huhtaniemi I, Raitakari O T. Increased carotid atherosclerosis in andropausal middle-aged men. J Am Coll Cardiol 2005; 45: 1603–1608
   PubMed Web of Science ®Google Scholar
• Fukui M, Kitagawa Y, Nakamura N, Kadono M, Mogami S, Hirata C, Ichio N, Wada K, Hasegawa G, Yoshikawa T. Association between serum testosterone concentration and carotid atherosclerosis in men with type 2 diabetes. Diabetes Care 2003; 26: 1869–1873
   PubMedGoogle Scholar
•  
   Google Scholar